BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:48 2024-05-15 am EDT			5-day change	1st Jan Change
239 ^SEK	+13.70%		+19.14%	-10.75%

06:46pm	Nordic Shares Moved Upward Wednesday; BioArctic Series B Topped Leaders	DJ
08:11am	BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	MT

Bioarctic AB Elects as a New Board Member

May 06, 2021 at 07:00 am EDT

BioArctic AB announced that Annual General Meeting held on May 6, 2021, Lotta Ljungqvist was elected as a new board member, all for a term of office extending until the end of the next annual general meeting.

Latest news about BioArctic AB

Nordic Shares Moved Upward Wednesday; BioArctic Series B Topped Leaders	12:46pm	DJ
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	02:11am	MT
Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest	Apr. 22	DJ
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	Apr. 20	CI
Nordic Shares Moved Upward Monday; Invisio Led Increases	Apr. 15	DJ
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	Apr. 12	DJ
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit	Mar. 22	DJ
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
Nordic Stocks Closed Up Wednesday; BioArctic Series B Topped Leaders Nordic Stocks	Feb. 14	DJ
Transcript : BioArctic AB, Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
BioArctic AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
BioArctic AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04	RE
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders	Jan. 18	DJ
Nordic Shares Decreased Thursday; Avance Gas Holding Took Biggest Hit	Jan. 11	DJ
European Medicines Regulator to Discuss Marketing Authorization for BioArctic's Alzheimer's Disease Drug	Jan. 11	MT
The European Medicines Agency's Scientific Advisory Group to Discuss the Marketing Authorisation Application for lecanemab	Jan. 11	CI
Nordic Stocks Decreased Tuesday; TGS Fell Furthest	Jan. 09	DJ
BioArctic's Partner Obtains Marketing Authorization for Leqembi in China	Jan. 09	MT
Leqembi® Approves for the Treatment of Alzheimer's Disease in China	Jan. 09	CI
Nordic Stocks Moved Upward Wednesday; Jeudan Climbed Highest	Dec. 13	DJ
BioArctic, Eisai Sets Launch Date for Alzheimer’s Disease Drug in Japan	Dec. 13	MT
Nordic Stocks Moved Upward Monday; Schibsted Led Increases	Dec. 11	DJ

Chart BioArctic AB

Duration

Period

More charts

Company Profile

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for BioArctic AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

239 SEK

Average target price

366.2 SEK

Spread / Average Target

+53.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOARCTIC AB	-10.75%	1.72B
MODERNA, INC.	+29.77%	49.18B
IQVIA HOLDINGS INC.	+1.00%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.71B
BIO-TECHNE CORPORATION	+8.22%	13.26B
MEDPACE HOLDINGS, INC.	+32.41%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.99B

Other Biotechnology & Medical Research